Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Peptech Announces Director Retirements

Peptech Announces Director Retirements

Peptech Limited (ASX:PTD, AIM: PTDx) today announced as part of its merger agreement with EvoGenix that Martin Kriewaldt and Till Medinger will retire as directors of the company, effective 28 August 2007.

Mel Bridges, Chairman of Peptech thanked both directors for the services provided to the company, commenting:

"Till has been a director of the company since 1997. He has been a consistent contributor at board level, with his international industry knowledge being particularly valuable. As Peptech's alternate director on the Domantis board, Till was instrumental in Peptech's continuing participation in Domantis and the very successful realisation of that investment.

"Since joining the Peptech Board in October 2003, Martin's litigation experience has been particularly invaluable in the disputes Peptech had with Centocor and Abbott. More recently he has used his skills in guiding Peptech through its merger and acquisition activity, spending considerable time on due diligence activities. "On behalf of the entire Peptech board I sincerely thank both these directors for their commitment to Peptech," he added.

Effective from 28 August 2007, Chris Harris and Robin Beaumont, formerly directors of EvoGenix Limited, will join the Peptech Board.

About Peptech:

Peptech Limited is a biotechnology company dedicated to developing and providing antibody and peptide-based human therapeutic products for the treatment of cancer and inflammatory diseases.

The Company has tapped its unique antibody technologies and revenues generated from its pioneering anti-TNF patents to build a range of therapeutic assets to address large and clinically validated markets.

Peptech is transitioning to a mid-stage development company as several products move from pre-clinical stages into human trials, starting with the Company's lead compound, PN0621, a differentiated anti-TNF domain antibody construct.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Trade Plans: Prime Minister's Speech To International Business Forum

"The work to improve public services, build infrastructure, and solve social problems is possible only because we have enjoyed sustained, solid economic growth. A big reason for that is the Government’s consistent agenda of economic reform, and our determination to open up more opportunities for trade with the world." More>>

ALSO:

Media: TVNZ Flags Job Cuts To Arrest Profit Decline

Chief executive Kevin Kenrick said the changes were aimed at creating "a sustainable future video content business for TVNZ in an ever-changing media market." More>>

ALSO:

Reserve Bank: Wheeler Keeps OCR At 1.75%

Reserve Bank governor Graeme Wheeler kept the official cash rate unchanged at 1.75 percent, as expected, and reiterated his view that the benchmark rate doesn't need shifting for the foreseeable future. More>>

ALSO:

f work for Pumpkin Patch staff

Retail: Pumpkin Patch Brand, IP Sold To Catch Group

The receivers of failed children's clothing retailer Pumpkin Patch have confirmed that the company's brand and intellectual property have been sold to Australian online retailer Catch Group. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news